Synthetic DNA technology is rapidly emerging as a key driver of innovation in the fields of medicine, biotechnology, and more. But it also poses significant risk, particularly in lowering barriers to the production of dangerous pathogens and toxins. At present, oversight of this technology is voluntarily coordinated among synthetic DNA providers and stakeholders, and detailed understanding of security processes, infrastructures, and insights from these providers is imperative to understand how to best mitigate the inherent risks of this technology.
No takes yet. Share an insight, caveat, or question.
Kane et al. (2024) studied this question.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: